SHASUNPHAR

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 16, 2015 titled "Shasun Pharmaceuticals receives USFDA approval for Carisoprodol Tablets".

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 27, 2015 titled "Shasun Pharmaceuticals Ltd announces strong Q2 FY 16 results".

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 30, 2015 titled "Shasun Pharmaceuticals Ltd announces Q1 FY16 results".

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 5, 2015 with respect to the financial results for the quarter ended December 31, 2014.

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 13, 2014, titled "Successful completion of US FDA inspection".

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 06, 2014, titled "Shasun Pharmaceuticals Limited announces Quarter 1 FY 15 results".

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 08, 2014, titled "Sucessful completion of US FDA and Mexican COFEPRIS inspection".

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 05, 2014, titled "Acquisition of Global rights of Ibuprofen 12 Hr Extended Release OTC & Nuprin brand"

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 24, 2013, titled "Successful completion of MHRA EU Inspection".

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 30, 2013, titled "Successful completion of MHRA EU Inspection".

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 17, 2013 titled "Successful completion of US FDA and Brazilian ANVISA inspection".

Shasun Pharmaceuticals Limited has informed the Exchange regarding a Press Release dated April 10, 2013, titled "Shasun Pharmaceuticals Ltd and Debiopharm Group(TM) enter into licensing agreement for the manufacturing and commercialization of Huperzine-A".

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 24, 2012, titled "Shasun announces Year ended 31st March 12 Results: Shasun achieved sales of Rs 1066 Crores and PAT of Rs 101 Crores in FY 12".

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 18, 2012, titled "Shasun turnover crosses Rs.1000 crores as it celebrates its 35 years of service to the pharmaceutical industry".

Shasun Chemicals And Drugs Limited has informed the Exchange regarding a press release dated August 27, 2010, titled "Shasun embarks into Nanotech: Announces collaboration with NBI".

Shasun Chemicals And Drugs Ltd. has informed the Exchange regarding a press release dated October 24, 2008, titled "Shasun Chemicals Q2FY09 revenues up 5% at Rs. 127 crore". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Shasun_PR_24102008.zip target=NEW> For more details click here.</a>

Shasun Chemicals And Drugs Ltd. has informed the Exchange regarding a press release dated July 26, 2008, titled "Shasun Chemicals posts Standalone Revenue of Rs. 103.23 crores in Q1FY09". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Shasun_Pr_26072008.zip target=NEW> For more details click here.</a>

Shasun Chemicals And Drugs Ltd. has informed the Exchange vide its letter dated June 05, 2008, regarding a press release dated June 04, 2008, titled "Shasun Chemicals FY08 Consolidated Revenue up 10.77% at Rs.887.20 crore; Board Recommends Final Dividend of 50%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Shasun_PR_05062008.zip target=NEW> For more details click here.</a>

Shasun Chemicals And Drugs Ltd. has informed the Exchange that: "Shasun Pharma Solutions Ltd a wholly owned UK Subsidiary of Shasun Chemicals And Drugs Limited, has entered into a non-exclusive licensing agreement with H-Lundback A/S a research based Danish Company". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Shasun_Det1_10072007.zip target=NEW> For more details click here.</a>

Shasun Chemicals And Drugs Ltd. has informed the Exchange that company has entered into a exclusive agreement with New-Jersey-based Alpharma Inc. for marketing its select generic formulations in US and Europe. Under this agreement, Shasun will develop and manufacture 10 generic formulations in specific dosage forms and strengths for exclusive distribution and marketing by Alpharma in the US and Europe. These ten oral formulations fall under speciality, chronic therapeutic segments such as cardio-vascular (CVS) and central nervous system (CNS) categories. Under the agreement, Alpharma would pro

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Company has signed a manufacturing and supply agreement for a pharmaceutical intermediate for a generic drug with Codexis Inc., USA, which is a privately held Biosciences company applying proprietary protein and strain engineering technologies to create novel process development solutions for efficient, cost-effective and environmentally friendly pharmaceutical manufacturing from 2002. Under terms of the agreement, Shasun will manufacture the pharmaceutical compound and Codexis will market the product worldwide to the generic p